Navigation Links
BioMS Medical Announces First quarter 2009 results
Date:5/11/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, May 11 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the first quarter, ended March 31, 2009.

"We remain on track to obtain the results from MAESTRO-01, the first of our two pivotal trials evaluating dirucotide in patients with secondary progressive multiple sclerosis, in the second half of 2009," said Kevin Giese, President and CEO of BioMS Medical. "We have demonstrated in previous trials that dirucotide has shown to be well tolerated and has the capacity to slow the progression of disease in certain genetically pre-disposed MS patients. If our pivotal trials confirm these results, we believe dirucotide could represent the first drug with blockbuster potential for the treatment of secondary progressive multiple sclerosis."

Currently, BioMS is conducting two pivotal clinical trials and one open-label follow-on trial of dirucotide for the treatment of secondary progressive MS (SPMS):

    -  MAESTRO-01: On January 22, 2007, BioMS announced that this pivotal
       phase III trial, being conducted in Canada and Western Europe, had
       completed full recruitment of 611 SPMS patients at 47 trial sites in
       ten countries. The primary clinical endpoint for MAESTRO-01 (and
       MAESTRO-03) is defined as a statistically and clinically significant
       increase in the time to progression of the disease as measured by the
       Expanded Disability Status Scale (EDSS), in patients with HLA-DR2
       and/or HLA-DR4 immune response genes.

       On April 21, 2009 the DSMB conducted a scheduled safety analysis and
       recommended that the trial continue to completion. To date, there have
       been ten positive safety reviews from the Data Safety Monitoring Board
       (DSMB) and this was the final scheduled review by 
'/>"/>
SOURCE  BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 

Related biology technology :

1. BioMS Medical to present at Alberta Economic Forum in Geneva
2. BioMS Medical to present at BioFinance 2009
3. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
5. BioMS Medical Announces 2008 Year End Results
6. BioMS Medical warrant extension
7. BioMS Medical to present at BIO CEO and Investor Conference
8. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
9. BioMS Medical recognized at Scrip Awards 2008
10. BioMS Medical Announces Third Quarter 2008 Results
11. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email: